Vehicle-controlled trials for indirect comparison of tacrolimus and pimecrolimus (proportion of patients with mild to moderate disease achieving treatment success at the end of 6 weeks)

TrialMean patient ageTacrolimus 0.03% (n=158)Pimecrolimus 1% (n=390)Vehicle (n=358)
Schachner 2005376.9 years50.6%N/A25.8%
Ho 20033613 monthsN/A54.5%23.8%
Eichenfield 200222 study #3056.7 yearsN/A37.7%16.2%
Eichenfield 200222 study #3076.8 yearsN/A32.1%20.6%
Pooled rate50.6%41.3%22.1%
95% CI(42.8% to 58.4%)(28.4% to 54.2%)(17.8% to 26.5%)
Heterogeneity statisticsCochrane’s QN/A14.5 (P<0.001)3.1 (P=0.38)
Indirect pooled relative risk (95% CI): 0.97 (0.63–1.48)
Excluding Ho, 2003a
Pooled rate34.7%21.4%
95% CI(29.0% to 40.4%)(15.6% to 27.3%)
Heterogeneity statisticsCochrane’s Q1.0 (P=0.32)2.97 (P=0.23)
Indirect pooled relative risk (95% CI): 1.05 (0.64 to 1.72)

a sensitivity analysis excluding Ho, 2003 were conducted to determine whether differences in age in this trial (among pimecrolimus trials) would significantly affect the pooled results.

From: Appendix E, Results for sensitivity analysis (Table 8)

Cover of Drug Class Review: Topical Calcineurin Inhibitors
Drug Class Review: Topical Calcineurin Inhibitors: Final Report [Internet].
Lee NJ, McDonagh M, Chan B, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.